{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:24:01Z","timestamp":1790965441840,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The present study aimed to assess the correlation of fibroblast growth factor (FGF)-23 expression with clinical characteristics, then further explore its value in predicting 2-year in-stent restenosis (ISR) risk in coronary heart disease (CHD) patients underwent percutaneous coronary intervention (PCI) with drug-eluting stent (DES).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective, single-center, observational study, totally 214 CHD patients treated by PCI with DES were consecutively recruited, and peripheral blood samples were collected prior to PCI with DES for serum samples isolation. Following, FGF-23 level in the serum samples was detected via enzyme linked-immuno-sorbent Assay. The follow-up coronary angiography was performed at 1\u00a0year and 2\u00a0years after PCI or if suspected ISR symptoms occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>FGF-23 was positively correlated with fasting blood-glucose, insulin resistance, serum creatinine, serum uric acid, LDL-C, high-sensitivity C-reactive protein, cardiac troponin I and N-terminal-proB-type natriuretic peptide, while was negatively associated with HDL-C and left ventricular ejection fraction (all<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Furthermore, FGF-23 was positively correlated with hypercholesteremia, hyperuricemia and family history of CAD (all<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). However, it did not correlate with other chronic complications, biochemical indexes, lesion features or PCI parameters (all<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). Moreover, FGF-23 level was higher in 2-year ISR patients (n\u2009=\u200938) compared to 2-year non-ISR patients (n\u2009=\u2009176) (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and receiver operating characteristic curve indicated that FGF-23 was of good value in predicting 2-year ISR risk (AUC 0.828, 95% CI 0.761\u20130.896).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree of target lesion, and serves as an independent risk factor for 2-year ISR risk in CHD patients underwent PCI with DES.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12872-020-01839-w","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T19:03:18Z","timestamp":1610046198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI"],"prefix":"10.1186","volume":"21","author":[{"given":"Tingting","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4396-6991","authenticated-orcid":false,"given":"Xianghua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"10","key":"1839_CR1","doi-asserted-by":"publisher","first-page":"16812","DOI":"10.1002\/jcp.28350","volume":"234","author":"AK Malakar","year":"2019","unstructured":"Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812\u201323.","journal-title":"J Cell Physiol"},{"key":"1839_CR2","doi-asserted-by":"publisher","first-page":"44789","DOI":"10.1038\/srep44789","volume":"7","author":"X Yang","year":"2017","unstructured":"Yang X, Li Y, Ren X, Xiong X, Wu L, Li J, Wang J, Gao Y, Shang H, Xing Y. Effects of exercise-based cardiac rehabilitation in patients after percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Sci Rep. 2017;7:44789.","journal-title":"Sci Rep"},{"issue":"10","key":"1839_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamacardio.2017.2895","volume":"2","author":"D Giacoppo","year":"2017","unstructured":"Giacoppo D, Colleran R, Cassese S, Frangieh AH, Wiebe J, Joner M, Schunkert H, Kastrati A, Byrne RA. Percutaneous coronary intervention vs coronary artery bypass grafting in patients with left main coronary artery stenosis: a systematic review and meta-analysis. JAMA Cardiol. 2017;2(10):1079\u201388.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"1839_CR4","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.2146\/ajhp150655","volume":"73","author":"JE Basaraba","year":"2016","unstructured":"Basaraba JE, Barry AR. What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation? Am J Health Syst Pharm. 2016;73(9):e229-237.","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"1839_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0735-1097(01)01742-9","volume":"39","author":"HC Lowe","year":"2002","unstructured":"Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol. 2002;39(2):183\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1839_CR6","first-page":"516","volume":"37","author":"PP Hao","year":"2010","unstructured":"Hao PP, Chen YG, Wang XL, Zhang Y. Efficacy and safety of drug-eluting stents in patients with acute ST-segment-elevation myocardial infarction: a meta-analysis of randomized controlled trials. Tex Heart Inst J. 2010;37(5):516\u201324.","journal-title":"Tex Heart Inst J"},{"issue":"3","key":"1839_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429\u201335.","journal-title":"J Bone Miner Res"},{"issue":"11","key":"1839_CR8","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393\u2013408.","journal-title":"J Clin Invest"},{"issue":"6","key":"1839_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/MED.0000000000000294","volume":"23","author":"J Batra","year":"2016","unstructured":"Batra J, Buttar RS, Kaur P, Kreimerman J, Melamed ML. FGF-23 and cardiovascular disease: review of literature. Curr Opin Endocrinol Diabetes Obes. 2016;23(6):423\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"1839_CR10","doi-asserted-by":"publisher","first-page":"e12902","DOI":"10.1111\/eci.12902","volume":"48","author":"JA Navarro-Garcia","year":"2018","unstructured":"Navarro-Garcia JA, Fernandez-Velasco M, Delgado C, Delgado JF, Kuro OM, Ruilope LM, Ruiz-Hurtado G. PTH, vitamin D, and the FGF-23-klotho axis and heart: going beyond the confines of nephrology. Eur J Clin Invest. 2018;48(4):e12902.","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"1839_CR11","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1159\/000495393","volume":"43","author":"F Lang","year":"2018","unstructured":"Lang F, Leibrock C, Pandyra AA, Stournaras C, Wagner CA, Foller M. Phosphate homeostasis, inflammation and the regulation of FGF-23. Kidney Blood Press Res. 2018;43(6):1742\u20138.","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"1839_CR12","doi-asserted-by":"publisher","first-page":"506","DOI":"10.20945\/2359-3997000000070","volume":"62","author":"D Tuzun","year":"2018","unstructured":"Tuzun D, Oguz A, Aydin MN, Kurutas EB, Ercan O, Sahin M, Unsal V, Ceren I, Akcay A, Gul K. Is FGF-23 an early indicator of atherosclerosis and cardiac dysfunction in patients with gestational diabetes? Arch Endocrinol Metab. 2018;62(5):506\u201313.","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"1839_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/MCA.0000000000000170","volume":"26","author":"LP Zhao","year":"2015","unstructured":"Zhao LP, Xu WT, Wang L, Li H, Shao CL, Gu HB, Chan SP, Xu HF, Yang XJ. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up. Coron Artery Dis. 2015;26(1):5\u201310.","journal-title":"Coron Artery Dis"},{"issue":"4","key":"1839_CR14","doi-asserted-by":"crossref","first-page":"E266","DOI":"10.1002\/ccd.23390","volume":"82","author":"GN Levine","year":"2013","unstructured":"Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013;82(4):E266-355.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"2","key":"1839_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/(SICI)1522-726X(199910)48:2<133::AID-CCD3>3.0.CO;2-H","volume":"48","author":"N Bruining","year":"1999","unstructured":"Bruining N, Sabate M, de Feyter PJ, Kay IP, Ligthart J, Disco C, Kutryk MJ, Roelandt JR, Serruys PW. Quantitative measurements of in-stent restenosis: a comparison between quantitative coronary ultrasound and quantitative coronary angiography. Catheter Cardiovasc Interv. 1999;48(2):133\u201342.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"2","key":"1839_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ccd.1810300205","volume":"30","author":"J Haase","year":"1993","unstructured":"Haase J, Escaned J, van Swijndregt EM, Ozaki Y, Gronenschild E, Slager CJ, Serruys PW. Experimental validation of geometric and densitometric coronary measurements on the new generation Cardiovascular Angiography Analysis System (CAAS II). Cathet Cardiovasc Diagn. 1993;30(2):104\u201314.","journal-title":"Cathet Cardiovasc Diagn"},{"issue":"2","key":"1839_CR17","doi-asserted-by":"publisher","first-page":"e22666","DOI":"10.1002\/jcla.22666","volume":"33","author":"Y Wu","year":"2019","unstructured":"Wu Y, Fu X. Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation. J Clin Lab Anal. 2019;33(2):e22666.","journal-title":"J Clin Lab Anal"},{"issue":"2","key":"1839_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0248-8663(03)00218-2","volume":"25","author":"A Lavoinne","year":"2004","unstructured":"Lavoinne A, Cauliez B. Cardiac troponin I and T: specific biomarkers of cardiomyocyte. Rev Med Interne. 2004;25(2):115\u201323.","journal-title":"Rev Med Interne"},{"key":"1839_CR19","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1002\/ehf2.12816","volume":"7","author":"C Roy","year":"2020","unstructured":"Roy C, Lejeune S, Slimani A, de Meester C, Ahn As SA, Rousseau MF, Mihaela A, Ginion A, Ferracin B, Pasquet A, et al. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail. 2020;7:2494\u2013507.","journal-title":"ESC Heart Fail"},{"issue":"22","key":"1839_CR20","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1016\/j.jacc.2014.03.026","volume":"63","author":"JA Udell","year":"2014","unstructured":"Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O\u2019Donnell TF, Vora AN, Omland T, Solomon SD, Pfeffer MA, et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol. 2014;63(22):2421\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1839_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1159\/000443241","volume":"42","author":"BI Freedman","year":"2015","unstructured":"Freedman BI, Divers J, Russell GB, Palmer ND, Bowden DW, Carr JJ, Wagenknecht LE, Hightower RC, Xu J, Smith SC, et al. Plasma FGF23 and calcified atherosclerotic plaque in African Americans with Type 2 diabetes mellitus. Am J Nephrol. 2015;42(6):391\u2013401.","journal-title":"Am J Nephrol"},{"issue":"4","key":"1839_CR22","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2337\/db14-1149","volume":"64","author":"ML Balestrieri","year":"2015","unstructured":"Balestrieri ML, Rizzo MR, Barbieri M, Paolisso P, D\u2019Onofrio N, Giovane A, Siniscalchi M, Minicucci F, Sardu C, D\u2019Andrea D, et al. Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment. Diabetes. 2015;64(4):1395\u2013406.","journal-title":"Diabetes"},{"issue":"2","key":"1839_CR23","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/jcp.29064","volume":"235","author":"N D'Onofrio","year":"2020","unstructured":"D\u2019Onofrio N, Sardu C, Paolisso P, Minicucci F, Gragnano F, Ferraraccio F, Panarese I, Scisciola L, Mauro C, Rizzo MR, et al. MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients. J Cell Physiol. 2020;235(2):1438\u201352.","journal-title":"J Cell Physiol"},{"issue":"2","key":"1839_CR24","first-page":"173","volume":"15","author":"L Pleva","year":"2018","unstructured":"Pleva L, Kukla P, Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review. J Geriatr Cardiol. 2018;15(2):173\u201384.","journal-title":"J Geriatr Cardiol"},{"issue":"9","key":"1839_CR25","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/ndt\/gft029","volume":"28","author":"RJ Johnson","year":"2013","unstructured":"Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013;28(9):2221\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"1839_CR26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1515\/jpem-2018-0507","volume":"32","author":"Y Kutluturk","year":"2019","unstructured":"Kutluturk Y, Akinci A, Ozerol IH, Yologlu S. The relationship between serum FGF-23 concentration and insulin resistance, prediabetes and dyslipidemia in obese children and adolescents. J Pediatr Endocrinol Metab. 2019;32(7):707\u201314.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"11","key":"1839_CR27","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3390\/nu9111273","volume":"9","author":"WCY Yip","year":"2017","unstructured":"Yip WCY, Sequeira IR, Plank LD, Poppitt SD. Prevalence of pre-diabetes across ethnicities: a review of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) for classification of dysglycaemia. Nutrients. 2017;9(11):1273.","journal-title":"Nutrients"},{"key":"1839_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3389\/fendo.2018.00278","volume":"9","author":"M Leifheit-Nestler","year":"2018","unstructured":"Leifheit-Nestler M, Haffner D. Paracrine effects of FGF23 on the heart. Front Endocrinol (Lausanne). 2018;9:278.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1839_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12933-019-0826-0","volume":"18","author":"FC Sasso","year":"2019","unstructured":"Sasso FC, Pafundi PC, Marfella R, Calabro P, Piscione F, Furbatto F, Esposito G, Galiero R, Gragnano F, Rinaldi L, et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. Cardiovasc Diabetol. 2019;18(1):24.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"1839_CR30","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1210\/jc.2012-1364","volume":"97","author":"R Marfella","year":"2012","unstructured":"Marfella R, Sasso FC, Siniscalchi M, Paolisso P, Rizzo MR, Ferraro F, Stabile E, Sorropago G, Calabro P, Carbonara O, et al. Peri-procedural tight glycemic control during early percutaneous coronary intervention is associated with a lower rate of in-stent restenosis in patients with acute ST-elevation myocardial infarction. J Clin Endocrinol Metab. 2012;97(8):2862\u201371.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1839_CR31","doi-asserted-by":"publisher","first-page":"e000434","DOI":"10.1161\/JAHA.113.000434","volume":"3","author":"D Torella","year":"2014","unstructured":"Torella D, Ellison GM, Torella M, Vicinanza C, Aquila I, Iaconetti C, Scalise M, Marino F, Henning BJ, Lewis FC, et al. Carbonic anhydrase activation is associated with worsened pathological remodeling in human ischemic diabetic cardiomyopathy. J Am Heart Assoc. 2014;3(2):e000434.","journal-title":"J Am Heart Assoc"},{"key":"1839_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1475-2840-6-35","volume":"6","author":"R Marfella","year":"2007","unstructured":"Marfella R, Di Filippo C, Siniscalchi M, Sasso FC, Ferraraccio F, Rossi F, Paolisso G. The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes. Cardiovasc Diabetol. 2007;6:35.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1839_CR33","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1210\/jc.2010-1382","volume":"96","author":"R Marfella","year":"2011","unstructured":"Marfella R, Ferraraccio F, Rizzo MR, Portoghese M, Barbieri M, Basilio C, Nersita R, Siniscalchi LI, Sasso FC, Ambrosino I, et al. Innate immune activity in plaque of patients with untreated and l-thyroxine-treated subclinical hypothyroidism. J Clin Endocrinol Metab. 2011;96(4):1015\u201320.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1839_CR34","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/dom.13122","volume":"20","author":"R Marfella","year":"2018","unstructured":"Marfella R, Sardu C, Calabro P, Siniscalchi M, Minicucci F, Signoriello G, Balestrieri ML, Mauro C, Rizzo MR, Paolisso G, et al. Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: effects of incretin treatment. Diabetes Obes Metab. 2018;20(3):723\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1839_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-017-0304-3","volume":"10","author":"R Marfella","year":"2018","unstructured":"Marfella R, Sardu C, Balestrieri ML, Siniscalchi M, Minicucci F, Signoriello G, Calabro P, Mauro C, Pieretti G, Coppola A, et al. Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis. Diabetol Metab Syndr. 2018;10:1.","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"1839_CR36","first-page":"441","volume":"92","author":"D Tousoulis","year":"2006","unstructured":"Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Heart. 2006;92(4):441\u20134.","journal-title":"Heart"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01839-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-020-01839-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01839-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T05:19:26Z","timestamp":1697519966000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01839-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1839"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01839-w","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"24 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethic Committee of The Second Hospital of Hebei Medical University, and all patients signed the informed consents.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}